Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Spring;6(1):10-13.

Targeted Lung Cancer Treatments and Eye Metastasis

Paul Zarogoulidis  1 , Sofia Baka  2 , Sofia Labaki  1 , George Lazaridis  3 , Georgia Trakada  4
Affiliations
Review

Targeted Lung Cancer Treatments and Eye Metastasis

Paul Zarogoulidis et al. Med Hypothesis Discov Innov Ophthalmol. 2017 Spring.

Abstract

Lung cancer remains the leading cause of death due to cancer. We do not have effective tools for the early detection of lung cancer, so patients are usually diagnosed at an advanced stage. However, novel therapies based on molecular pathways (such as those involving the epidermal growth factor receptor, anaplastic lymphoma kinase, serine/threonine-protein kinase B-Raf, proto-oncogene tyrosine-protein kinase ROS, c-Met proto-oncogene protein, and RET proto-oncogene protein) are now commonly used in the treatment of lung cancer. In particular, these therapies are considered as first-line treatments for non-small-cell lung cancer. This manuscript outlines previous research on these targeted treatments, focusing on whether they are effective against eye metastasis.

Keywords: Anaplastic Lymphoma Kinase; C-Met Proto-Oncogene Protein; Epidermal Growth Factor Receptor; Lung cancer; Proto-Oncogene Tyrosine-Protein Kinase ROS; RET Proto-Oncogene Protein; Serine/Threonine-Protein Kinase B-Raf.

PubMed Disclaimer

Conflict of interest statement

None declared. No funding or sponsorship was received for this study. All the aforementioned authors met the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have provided approval for the revised manuscript to be published.

References

    1. Nagpal M, Singh S, Singh P, Chauhan P, Zaidi MA. Tumor markers: A diagnostic tool. Natl J Maxillofac Surg. 2016 Jan-Jun;7(1):17–20. Review. PMID: 28163473.2. - PMC - PubMed
    1. Zhao W, Choi YL, Song JY, Zhu Y, Xu Q, Zhang F, Jiang L, Cheng J, Zheng G, Mao M. ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare. Lung Cancer. 2016 Apr;94:22–7. PMID: 26973202. - PubMed
    1. Shea M, Costa DB, Rangachari D. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Ther Adv Respir Dis. 2016 Apr;10(2):113–29. Review. PMID: 26620497. - PMC - PubMed
    1. Domvri K, Zarogoulidis P, Darwiche K, Browning RF, Li Q, Turner JF, Kioumis I, Spyratos D, Porpodis K, Papaiwannou A, Tsiouda T, Freitag L, Zarogoulidis K. Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy. J Cancer. 2013 Nov ;4(9):736–54. Review. PMID: 24312144. - PMC - PubMed
    1. Zarogoulidis K, Zarogoulidis P, Darwiche K, Boutsikou E, Machairiotis N, Tsakiridis K, Katsikogiannis N, Kougioumtzi I, Karapantzos I, Huang H, Spyratos D. Treatment of non-small cell lung cancer (NSCLC) J Thorac Dis. 2013 Sep;5 (Suppl 4):S389–96. Review. PMID: 24102012. - PMC - PubMed

LinkOut - more resources